

Clinically Aligned Pretreated PDX Models

Our new clinically aligned pretreated PDX models empower you to develop innovative drugs to address today's unmet needs in the clinic.



Clinically Aligned Pretreated PDX Models

Evaluate next-generation therapeutics with the most clinically relevant models reflecting the patient population and cancer treatments of today. Our newest cohort of clinically aligned PDX models represent patients who received multiple lines of treatment and include metastatic disease states collected from various biopsy sites and clinically relevant mutations.

Advantages of our Clinically Aligned Pretreated PDX Models

- **Models that reflect the patient populations and treatments currently in use today**

Crown Bioscience's pretreated PDX collection carries a wide selection of models coming from patients with different treatment histories, including those that are relevant to today's therapies, including KRAS inhibitors and immune checkpoint inhibitors. Furthermore, we carry models reflecting disease states with the highest unmet need, including advanced metastatic cancer.

- **Quickly find pretreated models for your research needs**

Crown Bioscience provides you with the tools to quickly identify the most relevant pretreated models for your specific patient profiles and test your next-generation drug candidates with confidence. Use our curated and searchable online [PDX database \(HuBase™\)](#) to identify your pretreated model by indication, or other criteria.

- **Flexibility and more preclinical options to boost your study (upstream and downstream capabilities)**

Crown Bioscience offers relevant services like mouse clinical trial support for stratifying patients, matching patient-derived xenograft organoids (PDXO) for screening and immuno-oncology platforms for the evaluation of immunotherapeutics, as well as genomic, proteomic, bioinformatic, and biomarker discovery support.

- **Reduce your project timelines with faster study initiation**

Our scientific project managers work with you to quickly set up your study with our pretreated PDX models that are maintained in a 'warm' state, so they are always ready for service - no tissue revival required.


Clinically Aligned Pretreated PDX Collection Key Facts:

- Over 90 clinically aligned pretreated PDX models covering 12 cancer types derived from patients of western origin with different drug treatments, including documented multiple lines of treatment.


- Treatments include immune checkpoint inhibitors, 3rd generation EGFRi, PARPi, KRASi, CDK4/6i, and BTKi.

- 45+ pretreated PDX models representing advanced, metastatic disease with samples collected from various biopsy sites.

Clinically Aligned Pretreated PDX Models by Indication



Clinically Aligned Pretreated PDX Models by Treatment



Newly Added Clinically Aligned Pretreated PDX Models (July 2023)

Our newest cohort of clinically aligned PDX models, listed in the table below, represent patients who received multiple lines of treatment and include metastatic disease states collected from various biopsy sites and clinically relevant mutations. Use our curated and searchable online [PDX database \(HuBase™\)](#) to view additional details for these models.

Model ID	Cancer type	Metastatic pathology diagnosis	Biopsy site	Treatment history	Comments
CR9523	Colorectal	Yes	Liver	1st FOLFOX, 2nd FOLFIRI	IRF1 copy number loss
CR9529	Colorectal	Yes	Retroperitoneal Lymph Node	1st FOLFOX + Avastin, 2nd FOLFIRI + Avastin, 3rd Lonsurf, 4th Investigational	N/A
CR9531	Colorectal	Yes	Small Bowel	1st FOLFIRI + Avastin	Slight Ulceration
CR9564	Colorectal	Yes	Left Lung Lingula	1st FOLFOX + Bevacizumab, 2nd FOLFIRI, 3rd Stivarga, 4th Lonsurf	N/A
CR9578	Colorectal	Yes	Left Lung	1st Capecitabine, 2nd FOLFOX, 3rd FOLFIRI	N/A
CR9668	Colorectal	Yes	Liver	1st FOLFOX, 2nd FOLFIRI, 3rd Investigational	KRAS G13D; PD-L1 Expression
CR9672	Colorectal	Yes	Liver	1st FOLFOX, 2nd Xeloda, 3rd FOLFIRI + Avastin, 4th Investigational, 5th Cancer Specific Plectin Antibody	N/A
LU9538	Lung Cancer	--	Right Lung	1st Carboplatin + Etoposide, 2nd Paclitaxel, 3rd Topotecan	NRAS G60R
LU9543	Lung Cancer	--	Right Chest Mass; Pleural Fluid	1st Pemetrexed + Pembrolizumab + Carboplatin	Slight ulceration, KRAS G12C; PD-L1 expression
LU9556	Lung Cancer	Yes	Retro Peritoneal Lymph Node	1st Gemcitabine + Carboplatin, 2nd Nivolumab, 3rd Atezolizumab, 4th Investigational, 5th Investigational, 6th Investigational	N/A
LU9575	Lung Cancer - NSCLC	No	Pleural Fluid	1st Pemetrexed + Carboplatin, 2nd Nivolumab, 3rd Investigational, 4th Investigational, 5th Investigational	N/A
MT9562	Mesothelioma	No	Pleural Fluid	1st Alimta + Cisplatin, 2nd Carboplatin + Alimta	N/A
OV9580	Ovarian Cancer	Yes	Pleural Fluid	1st Carboplatin + Taxol, 2nd Doxorubicin + Bevacizumab, 3rd Investigational, 4th Investigational	Rare atypical cells positive for metastatic high-grade serous carcinoma
PA9658	Pancreatic Cancer	--	Pancreas	1st Folfirinox, 2nd Gemcitabine + Abraxane	From same patient of PA9573, slight ulceration.



View All Available Data for our 350+ Pretreated PDX Models

To view data for specific pretreated models or browse models, register for or log into our free PDX database (HuBase™) at <https://www.crownbio.com/databases/hubase> to view treatment history, available validation (SOC) data, genomic, and proteomic data to help you find the best models for your research needs.

How to search pretreated PDX models by patient treatment history:

1. Select the "Pretreatment" toggle to filter all pretreated PDX models. The toggle feature will display all available pretreated PDX models, categorized by indication.
2. For each model, click on the "More" section to expand it and view the patient treatment history, as well as additional clinical and characterization data.

Callout 1: Select Pretreatment toggle to view all available pretreated PDX model data

Callout 2: Click on "More" section to expand to view treatment history and other characterization data for each model.

The screenshot shows the HuBase interface with the search bar containing 'CR9668'. The 'Pretreatment' filter is selected. The 'More' section is expanded, showing treatment history: '1st FOLFIRI, 2nd FOLFIRI, 3rd Investigational'. The summary section shows details for Model ID CR9668, including Cancer Type (CR-Colorectal Cancer), Subtype (ADC), Origin (Western), and Special Features (KRAS G13D, PD-L1 Expression).

3. To search by patient treatment history, enter the name of the treatment into the "Input KeyWords" search bar
4. Click on the orange search button with the looking glass icon below. This action will filter all models that contain the treatment name in their entries.*

Callout 1: Search by patient treatment history by entering name of treatment into "Input KeyWords" search bar. And click on the orange search button below.

Callout 2: All models that contain the entered treatment name in their entries will be filtered for you to select and view

The screenshot shows the HuBase interface with the search bar containing 'Pembrolizumab'. The 'Pretreatment' filter is selected. The search results are filtered to show 'Cancer Models' including 'HuPrime® cancer models(3)', 'CR-Colorectal Cancer(1)', 'ES-Esophageal Cancer(1)', 'HN-Head and Neck Cancer(1)', and 'LU-Lung Cancer(2)'. The 'More' section for model CR9524 is expanded, showing treatment history: '1st Fluorouracil + Oxaliplatin + Bevacizumab, 2nd Trifluridine-Tipiracil, 3rd FOLFIRI + Ziv-aflibercept, 4th Investigational, 5th Investigational, 6th Investigational+Pembrolizumab, Moderately differentiated adenocarcinoma (P1, P3)'. The summary section shows details for Model ID CR9524, including Cancer Type (CR-Colorectal Cancer), Subtype (ADC), Origin (Western), and Special Features (Complete Response to Investigational + Pembrolizumab, TCR Become Resistant 2 Years Later (Patient), Single Mutation).

*Please note that the patient treatment history listed in each entry is sourced directly from the clinic and is not standardized in HuBase™. This means that when searching for models based on patient treatment history, you may need to search for both the generic name (e.g., Pembrolizumab) and brand name (e.g., Keytruda) to ensure you find all models derived from patients treated with a specific treatment.

Get in touch



Sales

US: +1 858 622 2900

UK: +44 870 242 2900

busdev@crowbio.com

www.crowbio.com



Science

consultation@crowbio.com

